Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03802214 · ClinicalTrials.gov registry record
Ulcerative Colitis - Vedolizumab- With/Without Prior Exposure to Anti-TNF（Tumor Necrosis Factor）Therapy
A clinical trial, sponsored by Stanford University.
- Terminated
- Registry status
- 1
- Enrollment target
NCT03802214: Clinical Trial study, sponsored by Stanford University.
NCT03802214 is a clinical trial that was terminated before completion, run by Stanford University. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03802214 was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
A case-control study to evaluate the immunoinflammatory effect of prior exposure to anti-TNF therapy in patients with ulcerative colitis starting vedolizumab therapy
Primary Outcome
Analysis of blood and tissue leukocytes (T cells, B cells and Dendritic cells) in patients with and without prior anti-TNF exposure
Interventions
- DRUG Vedolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-10-29 |
| Est. Completion | 2020-12-11 |
Why NCT03802214 stopped before completion
NCT03802214 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Vedolizumab is the first listed.
NCT03802214 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03802214 about?
NCT03802214 is a clinical study titled "Ulcerative Colitis - Vedolizumab- With/Without Prior Exposure to Anti-TNF（Tumor Necrosis Factor）Therapy". A case-control study to evaluate the immunoinflammatory effect of prior exposure to anti-TNF therapy in patients with ulcerative colitis starting vedolizumab therapy
What is the current status of trial NCT03802214?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2020-10-29. Estimated completion is 2020-12-11.
What interventions are being tested in trial NCT03802214?
The interventions under investigation include: Vedolizumab (DRUG).
Who is sponsoring clinical trial NCT03802214?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI